Life Science Company News

James Cacioppo Acquires Additional Securities of Jushi Holdings Inc.

BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- James Cacioppo, Chairman and Chief Executive Officer of Jushi Holdings Inc. (the “Issuer”), located at 225 NE Mizner Blvd., Suite 720, Boca Raton, FL 33432 and Serpentine Capital Management II LLC (”Serpentine”), One East Partners, LP (“One East“), OEP Opportunities, LP (“OEP“) and JAC Serpentine, LLC (“JAC Serpentine”) (each of which are entities controlled by James Cacioppo and are collectively referred to herein with James Cacioppo as the “Acquirors”), announced today that the Acquirors have acquired beneficial ownership or control or direction over the following securities of the Issuer on the dates specified below (collectively, the “Specified Securities”):

DATE OF ACQUISITIONACQUIRORSECURITYNUMBER
1/3/2020SerpentineNotesUS$5,000,000 (the “January Notes”)
1/3/2020SerpentineWarrants3,000,000(1)
1/20/2020One EastNotesUS$2,500,000 (the “January Notes 2”)
1/27/2020OEPNotesUS$2,500,000 (the “January Notes 3”)
6/8/2020James CacioppoSubordinate Voting Shares133,197(2)
7/10/2020JAC SerpentineNotesUS$1,500,000 (the “July Notes”)
7/10/2020JAC SerpentineWarrants900,000(3)
7/11/2020One EastWarrants1,500,000(4)
7/11/2020OEPWarrants1,500,000(5)

Notes:
(1)  Acquired for no additional consideration in connection with the Acquirors’ acquisition of the January Notes.
(2)  Acquired for no additional consideration in connection with the Acquirors’ participation in the Issuer’s equity incentive plan.
(3)  Acquired for no additional consideration in connection with the Acquirors’ acquisition of the July Notes.
(4)  Acquired for no additional consideration in connection with the Acquirors’ acquisition of the January Notes 2.
(5)  Acquired for no additional consideration in connection with the Acquirors’ acquisition of the January Notes 3.

The Specified Securities represent in the aggregate, on an as converted basis, 5.74% of the Subordinate Voting Shares issued and outstanding (calculated on a non-diluted basis).

Following the acquisition of the Specified Securities, the Acquirors, together with their joint actors, have beneficial ownership, or control or direction over the following securities of the Issuer (collectively, the “Securities”):

SECURITYNUMBER(1)
10% Notes (non-convertible)US$11,500,000 
Class A Super Voting Shares (“Super Voting Shares”)114,000 
Subordinate Voting Shares1,789,289 
Warrants to acquire Super Voting Shares127,750 
Warrants to acquire Subordinate Voting Shares7,549,815 
Options to acquire Subordinate Voting Shares2,385,000 

Notes:
(1) The Securities represent approximately 29.29% of all of the issued and outstanding Subordinate Voting Shares, calculated in accordance with National Instrument 62-104 Take-Over Bids and Insider Bids.

This press release is issued pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which requires a report to be filed on SEDAR (www.sedar.com) containing additional information with respect to the foregoing matters. A copy of this report may be obtained by contacting Investor Relations, Jushi Holdings Inc., investors@jushico.com.

About Jushi Holdings Inc.
We are a globally focused cannabis and hemp company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis and hemp-derived assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis and hemp ecosystem. For more information please visit www.jushico.com or our social media channels, Instagram, Facebook, Twitter and LinkedIn.

Investor Relations Contact:
Michael Perlman
Executive Vice President of Investor Relations and Treasury
561-453-1308
Investors@jushico.com

Media Contact:
Ellen Mellody
MATTIO Communications
570-209-2947
Ellen@Mattio.com


By: GlobeNewswire - 13 Jul 2020
Back to overview

Enhance your business development with Biotechgate